Abstract: The present invention relates to the use of 4-(4-Fluoro-2-methoxyphenyl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine (compound A), more particularly (+)-4-(4-Fluoro-2-methoxyphenyl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine (compound A?), for treating leukemias, in particular acute leukemias, preferably acute myeloid leukemias.

Abstract: The present invention relates to the novel use of Prothioconazole for inducing host defence responses in a plant. In particular, the present invention relates the use of Prothioconazole for inducing systemic acquired resistance (SAR) in a plant.

Abstract: The present invention relates primarily to a process for preparing certain phosphorus-containing cyanohydrins of the formula (I), and also to certain phosphorus-containing cyanohydrins per se and to their use for the preparation of glufosinate and/or glufosinate salts. The present invention further relates to certain mixtures particularly suitable for preparing the phosphorus-containing cyanohydrins of the formula (I).

Abstract: A new process for the preparation of 5-fluoro-1H-pyrazoles of the general formula (I) as described herein comprising reacting an olefin with an hydrazine.

Abstract: A syringe for use with a medical injector system includes a barrel and a semi-rigid hub, the hub having an outer surface adapted to slidingly move within the barrel, and an inner surface having a continous circumferential wall. The hub further includes an annular engaging portion recessed within at least part of the continous circumferential wall forming a groove, at least one radially extendable and retractable retention member disposed at partially within a proximal cylindrical portion of the hub, and the elastometric seal engaged with a seal engaging portion on the hub and slidingly engaged with the barrel of the syringe. The semi-rigid hub and the elastomeric seal are reciprocally slidable within the barrel, and the at least one radially entendable and retractable retention member is configured to releasably engage the groove upon retraction of the plunger to permit the semi-rigid hub to be selectively withdrawn within the barrel.

Abstract: The present invention relates to a novel process for preparing cis-alkoxy-substituted spirocyclic phenylacetylamino acid esters and cis-alkoxy-substituted spirocyclic 1H-pyrrolidine-2,4-dione derivatives, and also to novel intermediates and starting materials which are produced and/or used in the process according to the invention.

Abstract: A high pressure medical connector tubing assembly includes a high pressure medical connector tubing assembly, including a tube element having opposed tube ends and a passageway, an end element overmolded to at least one of the opposed tube ends, the end element having an annular end portion having a preselected length, and a connector element having a connector hub defining a receiving cavity. The preselected length of the annular end portion may be used to pre-control the axial location of stress concentration in the connector hub. A method of forming the high pressure medical connector tubing assembly includes providing a tube element comprising opposed tube ends and a passageway therethrough, overmolding an end element onto at least one of the opposed tube ends, providing a connector element comprising a connector hub defining a receiving cavity, and securing the tube end with the overmolded end element in the receiving cavity.

Abstract: The invention relates to the use of single- or multilayer plastic web plates in a sloped channel-type solid material separator with a lamella package.

Abstract: The present invention relates to active compound combinations, in particular within a fungicide composition, which comprises (A) a N-cyclopropyl-N-[substituted-benzyl]-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide or thiocarboxamide derivative and two further fungicidally active compounds (B) and (C). Moreover, the invention relates to a method for curatively or preventively or eradicatively controlling the phytopathogenic fungi of plants or crops, to the use of a combination according to the invention for the treatment of seed, to a method for protecting a seed and not at least to the treated seed.

Abstract: The present application relates to novel bicyclic compounds, to their use for controlling animal pests and to processes and intermediates for their preparation.

Abstract: A device for the contamination-free filling of a tank from a canister is provided.

Abstract: A pressure isolation mechanism for use in a medical procedure includes a lumen, an isolation port in fluid connection with lumen, and a valve having a first state and a second state. The first state occurs when the lumen and the isolation port are connected. The second state occurs when the lumen and the isolation port are disconnected. The lumen remains open for flow of fluid therethrough in the first state and in the second state. The valve is normally in the first state and is switchable to the second state when fluid pressure in the lumen reaches a predetermined pressure level. A pressure transducer can be in fluid connection with the isolation port of the pressure isolation mechanism A fluid delivery system includes a manually operated syringe and a pressure isolation mechanism as described above.

Abstract: The present invention relates to protein-lysine N-methyltransferase SMYD2 (SET and MYND domain-containing protein 2) inhibitors, in particular SMYD2-inhibitory substituted cyanoguanidine-pyrazolines of general formula (I) wherein R1, R2, R3, R4, R5, X and r have the meaning as described and defined herein, as well as to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyper-proliferative disorders, in particular for cancer, respectively tumour disorders. The present invention furthermore relates to the use of SMYD2 inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility.

Abstract: The present invention relates to prodrug derivatives of Mps-1 kinase inhibitors, and their use for the treatment and/or prophylaxis of diseases.

Abstract: Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) and the isolated nucleic acid molecules encoding them are provided. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.

Abstract: The present invention relates to solid pharmaceutical dosage forms for oral administration comprising sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate (active ingredient (I)), characterized in that the active ingredient (I) is released, and also methods for the preparation thereof, use thereof as medicaments, and also use thereof for prophylaxis, secondary prophylaxis or treatment of disorders, particularly cardiovascular disorders, heart failure, anemia, chronic renal disorders and renal insufficiency.

Abstract: A tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyl solubilising group.

Abstract: The present invention relates to a composition comprising a) recombinant exosporium-producing Bacillus cells that express a fusion protein comprising: (i) at least one plant growth stimulating protein or peptide and (ii) a targeting sequence that localizes the fusion protein to the exosporium of the Bacillus cells; and b) at least one further biological control agent selected from particular microorganisms disclosed herein and/or a mutant of a specific strain of a microorganism disclosed herein having all identifying characteristics of the respective strain, and/or at least one metabolite produced by the respective strain, and/or at least one metabolite produced by the respective strain that exhibits activity against insects, mites, nematodes and/or phytopathogens in a synergistically effective amount. Furthermore, the present invention relates to the use of this composition as well as a method for enhancing plant growth, promoting plant health, and/or reducing overall damage of plants and plant parts.

Abstract: A medical connector includes a body defining a lumen for fluid flow through the medical connector. The medical connector includes a luer member and an annular member disposed about the luer member. The annular member includes internal and/or external engagement structures. The medical connector may be provided on the outlet of a syringe or on a catheter. A fluid path is disclosed including a first section and a second section. The first and second sections may each include a medical connector to provide a removable connection with a syringe and a catheter, respectively. The medical connector may provide a removable connection between the first and second sections. A fluid delivery system is disclosed including an injector, a syringe operatively associated with the injector, and a fluid path connecting the syringe and a source of injection. The medical connector may provide a removable connection between the syringe and fluid path.

Abstract: The present invention relates to a process for preparing 4-(4-[({[4-chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorophenoxy)-N-methylpyridine-2-carboxamide, its salts and monohydrate.